Drug Profile
Resolvine - Kato Pharmaceuticals
Alternative Names: Resolv ER; Resolvine; Resolvine ERLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator KATO Pharmaceuticals
- Developer KATO Pharmaceuticals; Ophthalmic Consultants of Boston
- Class Anti-inflammatories; Eye disorder therapies; Omega 3 fatty acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic retinopathy; Retinal disorders